As shown in Figures 1a and b, nuclear NFAT2 was detected in 42/83 of the ER−PR−HER2− (TNBC; triple-negative breast cancer) tumors, whereas only a minority of the luminal A, luminal B and HER2+ tumors showed nuclear NFAT2 staining (12/101, 16/85 and 4/52, respectively). Here, ERBB2 is linked to triple-negative breast carcinoma.